Antigen News and Research

RSS

Strong link between high HuR protein levels and malignancy of HCC

Researchers at CIC Biogune, the Cooperative Centre for Research into Biosciences and led by Dr. Maria Luz Martinez Chantar, have found a strong relationship between high levels of Hu antigen R (HuR) protein and the malignancy of Hepatocellular Carcinoma, through a novel molecular process in the investigation of this pathology and known as neddylation.

27 Jan 2012

Technoclone, Roche enter strategic alliance to co-develop coagulation assays

Roche announced today that it has entered into a strategic alliance with Technoclone, a reagent specialist in thrombosis and cardiovascular diagnostics based in Vienna, Austria, to co-develop a complete range of coagulation assays.

From Roche Sequencing and Life Science 27 Jan 2012

Dutaseride may help prevent progression of early stage prostate cancer: Study

A new study suggests that men with early stage prostate cancer may benefit with drugs that can slow or stop the cancer’s progress. Less than 10 percent of the 100,000 men each year who are diagnosed with early-stage prostate cancer and have the option of leaving the cancer in place. Rest get it removed using surgery or radiation. But those treatments can have serious side effects like impotence and incontinence.

24 Jan 2012

ImmunoCellular initiates enrollment in ICT-107 Phase II trial for GBM in 23 centers

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

24 Jan 2012

OPKO acquires two new prostate cancer biomarkers from Arctic Partners

OPKO Health, Inc. today announced the acquisition of an exclusive license from Arctic Partners Ab Oy for two biomarkers in the kallikrein family which, used together with prostate specific antigen (PSA), can reduce the need for prostate biopsies by over 50%.

24 Jan 2012

Dutasteride delays prostate cancer progression in men

For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a three-year international clinical trial led by Dr. Neil Fleshner, Head of the Division of Urology, University Health Network.

24 Jan 2012

Duke team creates vaccine adjuvant of nanoparticles that target lymph nodes

Researchers at Duke University Medical Center have created synthetic nanoparticles that target lymph nodes and greatly boost vaccine responses, said lead author Ashley St. John, Ph.D., a researcher at Duke-NUS Graduate Medical School.

23 Jan 2012

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

21 Jan 2012

Study investigates immune response in cancer

In a study investigating immune response in cancer, researchers from Moffitt Cancer Center in Tampa, Fla., and the University of South Florida have found that interaction between the immune system's antigen-specific CD4 T cells and myeloid-derived suppressor cells (MDSC) - cells that play a major role in cancer-related immune suppression - dramatically change the nature of MDSC-mediated suppression. By contrast, the same effect was not observed when MDSCs interacted with the immune system's CD8 T cells.

20 Jan 2012

Soligenix reports results from long-term stability studies of SGX204 anthrax vaccine

Soligenix, Inc., a development stage biopharmaceutical company, announced today results from long-term stability studies of its proprietary DNI anthrax rPA subunit protein vaccine, known as SGX204.

19 Jan 2012

LEITAT, JPT and IUCT partner to develop enhanced anticancer therapy

JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG, IUCT and LEITAT announced today their collaboration on the joint development of an enhanced anticancer therapy based on the biofocused targeting of nucleoside analogs linked to small cyclic peptidomimetics.

18 Jan 2012

New path for individually tailored cancer therapy

The Institute of Translational Oncology (TRON) together with BioNTech AG today announced the publication of a joint paper in the international journal Cancer Research that describes a new path for individually tailored cancer therapy.

18 Jan 2012

Study compares adoptive T-cell therapy with drug-based cancer treatment

In the treatment of large tumors, how effective is adoptive T cell therapy in comparison to drug-based cancer treatment? To answer this question, Dr. Kathleen Anders and Professor Thomas Blankenstein of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and researchers of the Beckman Research Institute of the City of Hope Cancer Center in Duarte, California, USA designed and carried out a study comparing the two methods. Based on a mouse cancer model, the researchers elucidated the mechanisms of the two different treatments.

18 Jan 2012

Pevion announces further data from clinical study of PEV7 therapeutic Candida vaccine

Pevion Biotech AG today announced further data from the ongoing clinical study of its therapeutic Candida vaccine PEV7, demonstrating the generation of specific and functional B cell memory in 100% of vaccinees. Furthermore, the results again confirm the capability of Pevion's second generation virosomal vaccine platform to induce strong and long-lasting immunity in humans against otherwise weak antigens .

17 Jan 2012

Non-toxin vaccine shows promise against lethal anthrax infection

Vaccination with the anthrax capsule-a naturally occurring component of the bacterium that causes the disease-protected monkeys from lethal anthrax infection, according to U.S. Army scientists. The study, which appears in the Jan. 20th print edition of the journal VACCINE, represents the first successful use of a non-toxin vaccine to protect monkeys from the disease.

13 Jan 2012

CMS increases NLA for T-SPOT.TB test's CPT code 86481

Oxford Immunotec, Inc. announces that, following a reconsideration request made by the company, the Centers for Medicare and Medicaid Services has increased the national limitation amount (NLA) for the Current Procedural Terminology (CPT) code 86481 which is used for the T-SPOT.TB test.

10 Jan 2012

Researchers create prostate cancer drug delivery system

Honing chemotherapy delivery to cancer cells is a challenge for many researchers. Getting the cancer cells to take the chemotherapy "bait" is a greater challenge. But perhaps such a challenge has not been met with greater success than by the nanotechnology research team of Omid Farokhzad, MD, Brigham and Women's Hospital (BWH) Department of Anesthesiology Perioperative and Pain Medicine and Research.

10 Jan 2012